There were no relevant differences between the treatment groups for patients in whom the area of greatest visual acuity is also affected. For other patients, data were lacking.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/T8tRX6AL9XM/141215101653.htm
Aflibercept in diabetic macular oedema: Added benefit not proven
15 diciembre 2014
Volver